Location: Boston, MA
CIK: 0001583977 · Show all filings
Period: Q4 2024 (← Previous) (Next →)
Filing Date: Feb 14, 2025
Total Value: $1.821B (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| MLTX | MOONLAKE IMMUNOTHERAPEUTICS | 8,494,151 | $460M | 25.3% | $12.22 | +317.8% | CLASS A ORD | 61559X104 |
| PRAX | PRAXIS PRECISION MEDICINES I | 1,693,219 | $130M | 7.2% | $53.98 | +34.0% | COM NEW | 74006W207 |
| JANX | JANUX THERAPEUTICS INC | 2,100,000 | $112M | 6.2% | $40.93 | +29.2% | COM | 47103J105 |
| ACLX | ARCELLX INC | 1,300,000 | $99.7M | 5.5% | $25.75 | +235.5% | COMMON STOCK | 03940C100 |
| EWTX | EDGEWISE THERAPEUTICS INC | 3,406,534 | $90.95M | 5.0% | $23.63 | +34.8% | COM | 28036F105 |
| NAMS | NEWAMSTERDAM PHARMA COMPANY | 3,250,000 | $83.53M | 4.6% | $20.31 | +4.6% | ORDINARY SHARES | N62509109 |
| EYPT | EYEPOINT PHARMACEUTICALS INC | 8,325,000 | $62.02M | 3.4% | $11.03 | -15.6% | COM NEW | 30233G209 |
| RAPP | RAPPORT THERAPEUTICS INC | 2,940,921 | $52.17M | 2.9% | $23.15 | -4.3% | COM | 75383L102 |
| CRNX | CRINETICS PHARMACEUTICALS IN | 1,000,000 | $51.13M | 2.8% | $24.75 | +126.0% | COM | 22663K107 |
| INSM | INSMED INC | 650,000 | $44.88M | 2.5% | $36.03 | +99.9% | COM PAR $.01 | 457669307 |
| BBIO | BRIDGEBIO PHARMA INC | 1,600,000 | $43.9M | 2.4% | $17.77 | +45.4% | COM | 10806X102 |
| CNTA | CENTESSA PHARMACEUTICALS PLC | 2,561,600 | $42.91M | 2.4% | $13.13 | — | SPONSORED ADS | 152309100 |
| DRUG | BRIGHT MINDS BIOSCIENCES INC | 1,059,331 | $38.16M | 2.1% | $35.19 | 0.0% | COM NEW | 10919W405 |
| PCVX | VAXCYTE INC | 425,000 | $34.79M | 1.9% | $53.56 | +85.4% | COM | 92243G108 |
| — | MERUS N V | 740,000 | $31.12M | 1.7% | $47.13 | — | COM | N5749R100 |
| BBOT | HELIX ACQUISITION CORP II | 2,909,000 | $30.54M | 1.7% | $10.35 | +1.5% | CL A ORD SHS | G4444H101 |
| RNAM | AVIDITY BIOSCIENCES INC | 1,050,000 | $30.53M | 1.7% | $37.44 | +11.6% | COM | 05370A108 |
| PHVS | PHARVARIS N V | 1,466,460 | $28.11M | 1.5% | $21.48 | -4.2% | COM | N69605108 |
| CRBP | CORBUS PHARMACEUTICALS HLDGS | 2,375,000 | $28.02M | 1.5% | $28.57 | -41.3% | COM NEW | 21833P301 |
| TARS | TARSUS PHARMACEUTICALS INC | 500,000 | $27.68M | 1.5% | $21.36 | +112.6% | COM | 87650L103 |
| AXSM | AXSOME THERAPEUTICS INC | 325,000 | $27.5M | 1.5% | $74.04 | +24.2% | COM | 05464T104 |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | 1,825,000 | $25.42M | 1.4% | $7.71 | +42.0% | COM | 03969K108 |
| RYTM | RHYTHM PHARMACEUTICALS INC | 400,000 | $22.39M | 1.2% | $19.33 | +185.8% | COM | 76243J105 |
| CGON | CG ONCOLOGY INC | 775,000 | $22.23M | 1.2% | $39.73 | -13.9% | COM | 156944100 |
| — | CARGO THERAPEUTICS INC | 1,182,563 | $17.05M | 0.9% | $23.15 | — | COM | 14179K101 |
| ALMS | ALUMIS INC | 2,147,396 | $16.88M | 0.9% | $13.30 | -24.6% | COM | 022307102 |
| OKUR | ONKURE THERAPEUTICS INC | 1,837,739 | $15.8M | 0.9% | $15.14 | 0.0% | COM CL A | 68277Q105 |
| AVBP | ARRIVENT BIOPHARMA INC | 585,462 | $15.6M | 0.9% | $20.47 | +40.2% | COM | 04272N102 |
| ABVX | ABIVAX SA | 2,130,000 | $15.59M | 0.9% | $10.70 | — | SPONSORED ADS | 00370M103 |
| ENGN | ENGENE HOLDINGS INC | 2,323,595 | $15.45M | 0.8% | $9.69 | -19.9% | COM | 29286M105 |
| BIOA | BIOAGE LABS INC | 2,629,529 | $15.22M | 0.8% | $18.97 | -9.1% | COM | 09077V100 |
| BMEA | BIOMEA FUSION INC | 3,570,872 | $13.85M | 0.8% | $17.07 | -53.3% | COM | 09077A106 |
| MBX | MBX BIOSCIENCES INC | 700,000 | $12.9M | 0.7% | $22.87 | -6.8% | COM | 55287L101 |
| SEPN | SEPTERNA INC | 560,000 | $12.82M | 0.7% | $23.65 | 0.0% | COM | 81734D104 |
| IBRX | IMMUNITYBIO INC | 3,000,000 | $7.68M | 0.4% | $4.17 | 0.0% | COM | 45256X103 |
| ELVN | ENLIVEN THERAPEUTICS INC | 250,000 | $5.625M | 0.3% | $25.92 | 0.0% | COM | 29337E102 |
| SPRY | ARS PHARMACEUTICALS INC | 500,000 | $5.275M | 0.3% | $14.01 | 0.0% | COM | 82835W108 |
| VYNE | VYNE THERAPEUTICS INC | 1,394,336 | $4.671M | 0.3% | $3.12 | -16.0% | COM | 92941V308 |
| KALA | KALA BIO INC | 603,027 | $4.185M | 0.2% | $6.30 | 0.0% | COM NEW | 483119202 |
| GHRS | GH RESEARCH PLC | 593,043 | $4.151M | 0.2% | $20.43 | -60.6% | ORDINARY SHARES | G3855L106 |
| — | Y-MABS THERAPEUTICS INC | 425,000 | $3.328M | 0.2% | $12.08 | — | COM | 984241109 |
| URGN | UROGEN PHARMA LTD | 300,000 | $3.195M | 0.2% | $14.22 | -15.8% | COM | M96088105 |
| OMER | OMEROS CORP | 300,000 | $2.964M | 0.2% | $6.86 | 0.0% | COM | 682143102 |
| STOK | STOKE THERAPEUTICS INC | 254,161 | $2.803M | 0.2% | $26.85 | -54.2% | COM | 86150R107 |
| BHVN | BIOHAVEN LTD | 55,539 | $2.074M | 0.1% | $43.60 | +7.0% | COM | G1110E107 |
| — | VERVE THERAPEUTICS INC | 350,000 | $1.974M | 0.1% | $49.89 | — | COM | 92539P101 |
| ARTV | ARTIVA BIOTHERAPEUTICS INC | 103,633 | $1.045M | 0.1% | $11.59 | +3.6% | COM | 04317A107 |
| — | RAPT THERAPEUTICS INC | 200,000 | $316K | 0.0% | $20.60 | — | COM | 75382E109 |